Oat Allergy: Report on 2 Cases

Tomás-Pérez M1, Iglesias-Souto FF2, Bartolome B3
1Department of Allergy, Hospital La Paz, Madrid, Spain
2Department of Allergy, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
3Roxall, R&D Department, Bilbao, Spain

doi: 10.18176/jiaci.0477

Key words: Oat allergy. Cereal allergy.

Palabras clave: Alergia a avena. Alergia a cereales.

Oat (Avena sativa) is a cereal from the Poaceae family that has become very popular in our setting due to its high nutritional value. All varieties of oats contain gluten and avenin, which is a prolamin similar to wheat gliadin. Oats are used as animal feed or as food in our diet, whether in grain, flour, or oat drinks. Despite the widespread consumption of this cereal, few cases of oat allergy have been described.

We report 2 cases of anaphylaxis to oat in patients who tolerated other cereals.

The first patient was a 14-year-old boy with a personal history of atopic dermatitis and recurrent croup. He consulted because he presented pruritus (pharynx, hands, and feet) and facial erythema with no other symptoms immediately after the ingestion of oat milk. The reaction resolved with antihistamines and corticosteroids in the emergency department. He had previously presented with oral pruritus after ingestion of oats. He tolerates wheat and other cereals.

Skin prick test (SPT) with the most common aeroallergens (dust mites, pollens, molds, pet dander) yielded a negative result. SPT to oat extract was positive (6×6 mm). Total IgE of 80 IU/mL, and specific IgE (CAP), in kU/L, was as follows: oat, 6.79; wheat, 0.38; rye, barley, corn, rice, Tri a 19, and Tri a 14, <0.35.

The second patient was a 62-year-old man with a personal history of ischemic heart disease, who developed anaphylaxis to oat milk. Within 5 minutes of ingestion, he developed oropharyngeal pruritus, dysphonia, and dyspnea, followed by acute generalized urticaria, which resolved after treatment with epinephrine, corticosteroids, and antihistamines in the emergency department. The patient did not take nonsteroidal antiinflammatory drugs or exercise before ingestion, and no other cofactors or possible triggers of the adverse reaction were identified. He currently tolerates all other types of cereals, except oat.

SPT performed with the most common aeroallergens (dust mites, pollens, molds, pet dander) yielded negative results. SPT performed with cereal extracts yielded a positive result to oat (10×9 mm), maize (10×10 mm), wheat (7×6 mm), rice (5×5 mm), and barley (6×5 mm). Total IgE was 82.40 IU/mL, and specific IgE (CAP), in kU/L, was as follows: oat, 40.10; wheat, 1.68; maize, 1.61; barley, 2.70; and rye, 2.04.
Protein extracts from oat milk and oat seed were prepared by homogenization in phosphate-buffered saline, dialyzation, and lyophilization. SDS-PAGE immunoblotting was carried out according to Laemmli under reducing conditions (with mercaptoethanol) with oat seed and oat milk extracts and sera from both patients. Serum from the first patient revealed IgE-binding bands of 34-35 kDa, 29.5 kDa, 28 kDa, and 22.5 kDa in oat milk extract and bands of 70 kDa, 50 kDa, 34-35 kDa, 26 kDa, and 22.5 kDa in oat seed extract. Analysis of serum from patient 2 revealed IgE-reactive bands of 55 kDa and 42 kDa in both oat extracts, as well as a faint 33-kDa band in oat seed extract.

We report 2 cases of allergy (anaphylaxis) due to ingestion of oat milk, one in an adult and the other in a child. In both cases, we demonstrated an IgE-mediated mechanism. Both patients were sensitized to wheat, and one (patient 2) was also sensitized to other cereals (rice, maize, and barley). Both patients tolerated all other types of cereal except oats. Regarding the identity of the IgE-binding proteins detected in the immunoblotting analysis, the 34-35-kDa band could correspond to an oat protein that is homologous to the wheat allergen Tri a 20 (molecular weight, 35-38 kDa), thus accounting for the slight sensitization to wheat in the first patient. The 22.5-kDa band could be a 12S oat seed globulin, and the band of around 50 kDa would correspond to a 48-kDa oat serpin previously described as an oat allergen in milk [1-3]. Only 3 bands were detected in the serum of the second patient (55, 42, and 33 kDa).

We found a further 3 cases of allergy to oats [4-6]. Inuo et al [4] described a case of anaphylaxis in a child with a positive SPT result against oat and wheat (although the patient tolerated wheat). This case resembles the first patient we report, where the molecular weights of the potential allergens were around 23 kDa, 30 kDa, and 35 kDa, the first of which could correspond to 12S seed storage proteins, as mentioned above. The second case we report could correspond to the 33-kDa protein identified. Prados-Castaño et al [3] reported a 48-kDa serpin from oat seed, which was identified using proteomic technology as the probable cause of an anaphylactic reaction after ingestion of oat milk. In the cases we report, we observed a band of around 45 kDa (42 kDa), which could correspond to this previously described serpin. Finally, Ototake et al [6] described a case of anaphylaxis induced by ingestion of oats with similar results in IgE-immunoblotting. The authors detected bands at approximately 25, 30, 33, and 45 kDa, as in the case of Inuo et al. In the cases we report, we detected bands of around 22.5 and 34-35 kDa in the first patient and bands of 42 and 33 kDa in the second patient, which could correspond to those reported by Inuo et al.

Despite being sensitized to other types of cereals, the patients in the present report are able to tolerate them, possibly because cereals (wheat, oats, rye) have homologous prolams and those of oat are less similar to each other [5].

We present 2 cases of allergy to oat with concomitant sensitization to other cereals that are well tolerated. We emphasize the importance of defining a specific sensitization profile in these patients in order to help us predict the importance of possible future allergic reactions.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**


Manuscript received October 14, 2019; accepted for publication January 7, 2020.

Margarita Tomas Pérez
Department of Allergy
Hospital La Paz
Paseo de la Castellana, 261
28046 Madrid, Spain
E-mail: margui.tomas@gmail.com

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience

Nettis E1, Bonzano L2, Patella V3, Detoraki A4, Trerotoli P5, Lombardo C6, on behalf of the Italian DADReL study group#

1 Allergist and Dermatologist Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy
2 Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
3 Division of Allergy and Clinical Immunology, Department of Medicine ASL Salerno, “Santa Maria della Speranza” Hospital, Battipaglia, Salerno, Italy
4 Department of Internal Medicine and Clinical Pathology, Azienda Ospedaliera Universitaria Federico II, Naples, Italy
5 Department of Biomedical Science and Human Oncology, University of Bari - Aldo Moro, Bari, Italy
6 Division of Dermatology “U.O. Multizonale APSS”, Santa Chiara Hospital, Trento, Italy

Key words: Atopic dermatitis. Conjunctivitis. Dupilumab.
Palabras clave: Dermatitis atópica. Conjuntivitis. Dupilumab.

Dupilumab was recently approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD), for which current treatment options are limited [1]. Dupilumab binds to the IL-4Rα subunit and blocks the signaling of IL-4 and IL-13, thereby inhibiting the release of proinflammatory cytokines, chemokines, and IgE [2,3]. Although generally well-tolerated, high rates of unspecified conjunctivitis have been reported in patients on dupilumab [2-4].

This multicenter prospective observational study involved 15 secondary care centers as a task force for the Italian Society of Allergy, Asthma, and Clinical Immunology. The aim was to investigate the baseline factors associated with the incidence of dupilumab-induced conjunctivitis. Ninety-six patients with severe AD—defined as an Eczema Area and Severity Index (EASI) score ≥24—and with inadequate response to/intolerance of cyclosporin A (CsA), or medically classified as unsuitable for CsA treatment, were enrolled and treated with a 600-mg loading dose and subsequent biweekly 300-mg injections of dupilumab for 16 weeks. During treatment, the investigators diagnosed, reported, and determined the severity and type of conjunctivitis (conjunctivitis; conjunctivitis, bacterial; conjunctivitis, viral; conjunctivitis, allergic; and #The members of the Italian DADReL (Dupilumab Atopic Dermatitis in Real Life) Study Group are listed in the

Acknowledgments